Sean Maduck's Transactions in Corcept Therapeutics Inc.

Sean Maduck, President of Corcept Endocrinology, reported several transactions involving Corcept Therapeutics Inc. (CORT) common stock. On June 12, 2025, Maduck transferred 10,024 shares to the Sean and Molly Maduck Living Trust and received 10,024 shares from the same trust. On July 3, 2025, he transferred 40,000 shares to the SNM 2025 Grantor Retained Annuity Trust and received 40,000 shares from the same trust. On August 1, 2025, Maduck exercised stock options to acquire 35,007 shares at $5.05 per share and sold 34,007 shares at weighted average prices ranging from $67.17 to $69.74 per share. These sales were made pursuant to a 10b5-1 plan. As of August 1, 2025, Maduck directly owned 7,681 shares and indirectly owned shares through various trusts and entities.